Quark Publishes Data Linking Proprietary Target to Pulmonary Injury, Emphysema

The new data in pulmonary injury and emphysema provide "support for additional clinical applications of this drug, such as treatment of acute and chronic lung injury," according to a company official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.